Brought to you by 
Public offering nets $43.2mm for Syros
09 Feb 2018
Executive Summary
Syros Pharmaceuticals Inc. (gene expression research for cancer drug development) netted $43.2mm through a public offering of 4.8mm common shares (including the overallotment) at $9.55. Through a separate private placement, Incyte (partner under an alliance signed earlier in January) exercised an option to buy 125,626 shares at the offering price.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public offering nets $43.2mm for Syros
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice